Alder BioPharmaceuticals Inc. co-founder Randy Schatzman has stepped down as president and CEO as the migraine drug maker is preparing to apply for Food and Drug Administration approval.

The Bothell-based pharmaceutical developer appointed board member Paul Cleveland as interim president and CEO effective Tuesday. Cleveland will remain on the board.

Schatzman gave up his seat on the board, but will serve as a consultant for 18 months. Alder BioPharmaceuticals called the move a “mutual decision”…

Seattle Biz Journal
Alder BioPharmaceuticals CEO steps down as migraine drug maker nears FDA approval